Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 195.00 195.00 196.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 25.4 15.5 2.3 83.3 1,305

Syncona Share Discussion Threads

Showing 18801 to 18824 of 18900 messages
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
DateSubjectAuthorDiscuss
17/12/2020
15:20
Syncona has been my single largest investment @ £1.34, so it is reasonable to say I am pleased with the performance so far.
luxaeterna1
17/12/2020
15:08
True, Freeline has raised significantly over the last two months, after the latest Phase 2 data and news of Phase 3 in 2021. NASDAQ Freeline price went from $1.70 to $18 over the last 3 months. ~ $650m MCAP now.
luxaeterna1
17/12/2020
14:35
Autolus still in the doldrums though? Tough market the CAR-Ts. Freeline looks good, positive data
1seanshare
17/12/2020
13:56
Why so perky today? Am liking the recent AUTOLUS news. Strong movements, bigger markets, outpatient dosing looking positive.
luxaeterna1
07/12/2020
07:57
Autolus presents additional data on AUTO1 05 December 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ: AUTL) (Autolus), announced new data highlighting progress on its AUTO1 program, the company's CAR T cell therapy being investigated in the ongoing ALLCAR Phase 1 study in relapsed / refractory adult B-Acute Lymphocytic Leukemia (ALL), during the American Society of Hematology (ASH) All-Virtual Annual Meeting, held between December 5-8, 2020. A copy of the announcement is set out below. Autolus noted that data from the ALLCAR study suggests AUTO1's potential for transformational activity in adult patients with relapsed / refractory ALL. The company also noted that the Phase 1b/2 pivotal study for the AUTO1 programme is under way and enrolment projections have had to be adjusted in light of the COVID-19 pandemic. The company now expects to enroll patients throughout 2021 with a full data set in 2022. Autolus management will host a conference call and webcast at 4:00 pm ET/9:00 pm GMT on Monday, 7th December, to discuss the ASH data. To listen to the webcast and view the accompanying slide presentation, please go to: hxxps://www.autolus.com/investor-relations/news-and-
brexitplus
02/12/2020
08:50
Lots of news in the last couple of days.
brexitplus
26/11/2020
15:49
Interesting - new presentation on Autolus website. They appear to be expanding AUTO1 from the ALL trials, for use in iNHL & CLL & Primary CNS Lymphoma. I suppose it is the same root cause in different parts of the body. More customers...? Good news considering the ALL trial results (80-90% complete response rate).
luxaeterna1
20/11/2020
22:14
The results webcast is available: htTps://www.synconaltd.com/investor-centre/results-and-presentations/
rambutan2
06/11/2020
15:36
Some real smart ppl on here. I bought this purely on a punt a while back, no real idea what the Co actually does or how it makes money lol, but nice rise today!
chc15
23/10/2020
14:27
Sorry need to change the link to see it working: httPs://youtu.be/k9-4p4DLH-0
luxaeterna1
23/10/2020
14:26
hxxps://youtu.be/k9-4p4DLH-0 Video interview from the team running the DLBCL trial She seems very happy with the results, it seems they are looking for an outpatient treatment regime (sending people home, rather than clogging up beds). This is very good news - if true a substantial de-risk on a 2nd condition.
luxaeterna1
23/10/2020
12:59
Some nice updates this week about the DLBCL trials. Once again reasonably solid results in a difficult environment. 71% of patients seeing clear benefits - with 64% reporting a 'complete response'. Thankfully showing reasonable safety profiles. They have clearly started a higher throughput of patients now and getting more confidence. They had 35 patients dosed in the trial at the data cut-off (around 3 months ago), so it is likely they have 35-45 patients enrolled now. After so long on the ALL trials, it is nice to start seeing depth on other conditions.
luxaeterna1
07/10/2020
15:10
Yes I understand the market quite well. Currently available CAR-Ts are only currently licensed for childhood ALL and some adult B-cell lymphomas. There is another which will soon get a licence for some myelomas. It's not for solid tumours, as yet. The PD-1s and CTLA-4 cover those off from a immunotherapy point of view. My comments on the hassle factor come from real clinicians treating patients with these haematological malignancies.
1seanshare
07/10/2020
14:41
It has largely focussed on late-stage unresponsive "difficult" cases admittedly, but they are also about to start testing ALL cancer by AUTOLUS using outpatient (i.e. not treated in permanent intensive care). I do not think it will be useful for 100% of cancers, but it already has a limited application and this is likely to grow over time. Altering patient immune systems is not simple - but if the patient is dying, you can ethically consider CAR-T.
luxaeterna1
07/10/2020
13:58
I worry about the whole CAR-T space. It's not the panacea that was initially hyped and the logistics of delivering the therapy is proving too onerous for many providers...
1seanshare
07/10/2020
13:28
If Autolus is as good as expected, it should be getting very interesting by around April. By that point they will have moderate P1/2 data on 5 cancer types, with 1x solid trial in phase 3 (ALL cancer) and 7 new cancer sub-types being initiated. Autolus is wobbling around a bit, but the market still values it in excess of 600 million. So that's not bad, all things considered.
luxaeterna1
06/10/2020
21:32
Any projections for the end Sept NBV which will be announced before long?
greygrey
06/10/2020
17:56
Autolus stock very depressed though.... hopefully this will pick up soon
1seanshare
06/10/2020
17:25
5 Autolus trials ongoing, 5+ more to start by end of 2021... cranking up a gear.
luxaeterna1
06/10/2020
15:29
I missed this in September “Syncona makes two new investments – Resolution Therapeutics and Neogene Therapeutics Resolution Therapeutics Following a collaboration agreement with the University of Edinburgh in 2018, Resolution has been founded by Syncona as a cell therapy company investigating the use of macrophages for the treatment of patients with end stage liver disease. In pre-clinical studies, macrophages have been well-documented as key agents of wound and injury repair in the liver, amongst other organs, and there is a growing body of evidence suggesting their use as therapeutic agents to treat cirrhosis of the liver caused by chronic liver diseases. Liver disease is a major burden on society, with 1-2 million people diagnosed with compensated liver cirrhosis in the US and EU5 per year. Current treatments, including lifestyle changes in the first instance, do not actively repair the liver, relying on early diagnosis before the onset of cirrhosis to be effective. There is therefore a strong unmet need for a regenerative therapy for patients with end stage liver disease. Syncona has founded Resolution with a £26.8m commitment to a Series A financing, investing an initial first tranche of £0.4m to fund the formation of the team and intellectual property (IP) required to commence operations. The investment follows an earlier seed investment in 2018 of £1.4m which funded discovery work in the laboratory of Professor Stuart Forbes, a leading figure in the field of macrophages and liver regeneration and Professor of Transplantation and Regenerative Medicine at the University of Edinburgh. Syncona’s holding value in Resolution is £1.8m and, at the point full current commitments are invested, the company will have a 79% stake in Resolution. Martin Murphy, chief executive of Syncona Investment Management Limited, and Ed Hodgkin, partner, have joined the Resolution board as non-executive directors. Neogene Therapeutics Syncona has co-led the $110.0m Series A financing round of Neogene, with a commitment of $19.0m (£14.8m) alongside specialist investors including EcoR1, Jeito Capital, Vida Ventures, Bellco Capital, Two River, and TPG, of which the first tranche of $15.2m (£11.9m) has been invested. The investment is valued at cost. Neogene was founded in 2019 around the work of world-class founders, Dr Ton Schumacher and Dr Carsten Linnemann, and is developing an engineered cell therapy product for solid tumours based on a patient’s own neoantigens. The Series A financing is intended to fund non-clinical validation of the company’s proprietary tumour-specific T-cell receptor gene isolation platform and a future Phase I study. Elisa Petris, partner of Syncona Investment Management Limited, has taken up the role of non-executive director on the Neogene board.”
brexitplus
30/9/2020
15:17
I'm with you there acuere
robow
30/9/2020
15:08
Been in these about 2/3 years now. Never can work out the catalyst for it going on a sustained fall or rise. With hindsight I could have built a decent stake by trading the peaks and troughs but Sod’s law says the time I sell at 260 plus it will go on a run to 300+ and never look back. Hopefully these rises will continue.
acuere
23/9/2020
21:12
i agree that with all this good news why no action on SYNC. It just does not respond to anything at present.
greygrey
23/9/2020
14:32
Freeline announces supply agreement for haemophilia B program Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company”; or “Freeline̶1;), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (“Thermo Fisher”). This agreement secures dedicated production capacity and resources for Freeline from 2021 to 2027, inclusive. This will provide capacity for the planned Phase 2b/3 pivotal clinical trial and potential commercialisation of Freeline’s haemophilia B program, FLT180a, using the Company’s proprietary manufacturing platform and processes.
brexitplus
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
ADVFN Advertorial
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220817 07:03:57